Inoviv
@inoviv.bsky.social
Inoviv uses a novel technology platform based on targeted proteomics to support pharmaceutical companies with biomarker test development.
inoviv.com
inoviv.com
What a week at the #ADPD2025 conference in Vienna!
A key takeaway? There’s growing momentum around novel #biomarker discovery and using targeted #proteomics to develop fit-for-purpose assays — from AD and PD to ALS and beyond.
If we missed you at the booth, let’s fix that! hubs.la/Q03gNJFz0
A key takeaway? There’s growing momentum around novel #biomarker discovery and using targeted #proteomics to develop fit-for-purpose assays — from AD and PD to ALS and beyond.
If we missed you at the booth, let’s fix that! hubs.la/Q03gNJFz0
April 10, 2025 at 3:48 PM
What a week at the #ADPD2025 conference in Vienna!
A key takeaway? There’s growing momentum around novel #biomarker discovery and using targeted #proteomics to develop fit-for-purpose assays — from AD and PD to ALS and beyond.
If we missed you at the booth, let’s fix that! hubs.la/Q03gNJFz0
A key takeaway? There’s growing momentum around novel #biomarker discovery and using targeted #proteomics to develop fit-for-purpose assays — from AD and PD to ALS and beyond.
If we missed you at the booth, let’s fix that! hubs.la/Q03gNJFz0
MasterKey™ v1.3 is here — now with 500+ new CNS-relevant proteins added to our 3,000+ protein catalog. From AD to ALS, build high-precision multiplexed assays for #neurological disease research and clinical trial support.
Explore the update - inoviv.com/masterkey/
#proteomics #biomarkers
Explore the update - inoviv.com/masterkey/
#proteomics #biomarkers
April 3, 2025 at 4:24 PM
MasterKey™ v1.3 is here — now with 500+ new CNS-relevant proteins added to our 3,000+ protein catalog. From AD to ALS, build high-precision multiplexed assays for #neurological disease research and clinical trial support.
Explore the update - inoviv.com/masterkey/
#proteomics #biomarkers
Explore the update - inoviv.com/masterkey/
#proteomics #biomarkers
We're live at the #ADPD2025 Conference in Vienna!
Visit Inoviv at booth #82 to discuss key tactics for developing fit-for-purpose proteomic assays in neurological drug development.
We look forward to speaking with you! hubs.la/Q03fyQYf0
Visit Inoviv at booth #82 to discuss key tactics for developing fit-for-purpose proteomic assays in neurological drug development.
We look forward to speaking with you! hubs.la/Q03fyQYf0
April 2, 2025 at 3:15 PM
We're live at the #ADPD2025 Conference in Vienna!
Visit Inoviv at booth #82 to discuss key tactics for developing fit-for-purpose proteomic assays in neurological drug development.
We look forward to speaking with you! hubs.la/Q03fyQYf0
Visit Inoviv at booth #82 to discuss key tactics for developing fit-for-purpose proteomic assays in neurological drug development.
We look forward to speaking with you! hubs.la/Q03fyQYf0
Accelerate #biomarker discovery with high-res #MassSpectrometry
Inoviv’s Q2 offer supports unbiased #proteomics on timsTOF or Astral platforms—ideal for translational scientists and #biotech teams exploring new markers or translating to targeted assays.
Learn more- inoviv.com/discovery-poc/
Inoviv’s Q2 offer supports unbiased #proteomics on timsTOF or Astral platforms—ideal for translational scientists and #biotech teams exploring new markers or translating to targeted assays.
Learn more- inoviv.com/discovery-poc/
Discovery Proteomics Proof of Concept Study - Inoviv
Inoviv’s Proof of Concept Study is designed to offer high-resolution discovery proteomics optimized for complex sample sets. Gain access to flexible data outputs, cutting-edge mass spectrometry, and e...
inoviv.com
March 26, 2025 at 7:29 PM
Accelerate #biomarker discovery with high-res #MassSpectrometry
Inoviv’s Q2 offer supports unbiased #proteomics on timsTOF or Astral platforms—ideal for translational scientists and #biotech teams exploring new markers or translating to targeted assays.
Learn more- inoviv.com/discovery-poc/
Inoviv’s Q2 offer supports unbiased #proteomics on timsTOF or Astral platforms—ideal for translational scientists and #biotech teams exploring new markers or translating to targeted assays.
Learn more- inoviv.com/discovery-poc/
Missed our latest blog featured on Scientist.com? Dive into how #MassSpectrometry based #proteomics is shaping #biomarker driven drug development.
Read the blog here — inoviv.com/blog-bridging-discovery-clinical-translation-inokey-for-biomarker-driven-drug-development/
Read the blog here — inoviv.com/blog-bridging-discovery-clinical-translation-inokey-for-biomarker-driven-drug-development/
Bridging Discovery & Clinical Translation: InoKey™ for Biomarker-Driven Drug Development - Inoviv
InoKey™ represents a significant advancement in proteomics, offering a disease-agnostic platform that empowers researchers worldwide. By bridging the translational biomarker gap, it facilitates the de...
inoviv.com
March 7, 2025 at 6:02 PM
Missed our latest blog featured on Scientist.com? Dive into how #MassSpectrometry based #proteomics is shaping #biomarker driven drug development.
Read the blog here — inoviv.com/blog-bridging-discovery-clinical-translation-inokey-for-biomarker-driven-drug-development/
Read the blog here — inoviv.com/blog-bridging-discovery-clinical-translation-inokey-for-biomarker-driven-drug-development/
NeuroKey-3™ uses #MassSpectrometry to quantify #biomarkers of neuroinflammation and synaptic health, aiding drug development and disease monitoring. With absolute quantification, it delivers high-confidence data on key markers like #BDNF, #NRGN, and IL-18.
Read our tech note: inoviv.com/neurokey-3/
Read our tech note: inoviv.com/neurokey-3/
NeuroKey-3 - Inoviv
NeuroKey-3 is a fully quantitative multiplexed IP-MS sssay to measure key low-level markers (BDNF, IL-18 & NRGN) linked to neurodegeneration
inoviv.com
February 26, 2025 at 5:56 PM
NeuroKey-3™ uses #MassSpectrometry to quantify #biomarkers of neuroinflammation and synaptic health, aiding drug development and disease monitoring. With absolute quantification, it delivers high-confidence data on key markers like #BDNF, #NRGN, and IL-18.
Read our tech note: inoviv.com/neurokey-3/
Read our tech note: inoviv.com/neurokey-3/
As mass spectrometry becomes more integrated into clinical research, which application holds the most promise?
1️⃣ Disease stratification
2️⃣️ Treatment efficacy monitoring
3️⃣ Biomarker-driven drug development
4️⃣ Regulatory assay development
📊 Show results
1️⃣ Disease stratification
2️⃣️ Treatment efficacy monitoring
3️⃣ Biomarker-driven drug development
4️⃣ Regulatory assay development
📊 Show results
February 19, 2025 at 5:35 PM
As mass spectrometry becomes more integrated into clinical research, which application holds the most promise?
1️⃣ Disease stratification
2️⃣️ Treatment efficacy monitoring
3️⃣ Biomarker-driven drug development
4️⃣ Regulatory assay development
📊 Show results
1️⃣ Disease stratification
2️⃣️ Treatment efficacy monitoring
3️⃣ Biomarker-driven drug development
4️⃣ Regulatory assay development
📊 Show results
Advancing #proteomics for #clinical impact. Inoviv’s latest blog explores the development and validation of a COVID-19 #proteomic assay, enabling precision in disease staging and treatment escalation.
Read more - inoviv.com/blog-bridgin...
#biopharma #biomarkers #massspec #precisionmedicine
Read more - inoviv.com/blog-bridgin...
#biopharma #biomarkers #massspec #precisionmedicine
Bridging Discovery & Clinical Translation: InoKey™ for Biomarker-Driven Drug Development - Inoviv
InoKey™ represents a significant advancement in proteomics, offering a disease-agnostic platform that empowers researchers worldwide. By bridging the translational biomarker gap, it facilitates the de...
inoviv.com
February 11, 2025 at 5:26 PM
Advancing #proteomics for #clinical impact. Inoviv’s latest blog explores the development and validation of a COVID-19 #proteomic assay, enabling precision in disease staging and treatment escalation.
Read more - inoviv.com/blog-bridgin...
#biopharma #biomarkers #massspec #precisionmedicine
Read more - inoviv.com/blog-bridgin...
#biopharma #biomarkers #massspec #precisionmedicine